Form 4: Immunome Inc. Executive Exercises Stock Options
SEC Form 4 Filing
Jack Higgins, Chief Scientific Officer of Immunome Inc., exercised stock options to acquire 5,200 shares of common stock at $1.35 per share on March 27, 2025.
Summary
- On March 27, 2025, Jack Higgins, the Chief Scientific Officer of Immunome Inc., exercised stock options to purchase 5,200 shares of Immunome Inc. common stock.
- The exercise price was $1.35 per share.
- Following the transaction, Higgins directly owns 18,729 shares of common stock.
- Higgins also directly owns 173,840 derivative securities in the form of employee stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive stock option exercise.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with shareholder interests.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| May 1, 2023 | 25% of the shares vested. |
| 03/27/2025 | Jack Higgins exercised stock options to acquire 5,200 shares of common stock. |
| 03/28/2025 | Date of signature of the report. |
| 06/23/2032 | Expiration date of the employee stock options. |
Keywords
Immunome Inc., Stock Options, Form 4, Executive Compensation, Insider Trading, IMNM, Jack Higgins, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.